Supplementary Appendix

Item	Kenya	Nigeria	South Africa	Tanzania	Sources	Other Information
Calibrated blood- collection drape*	1.52	1.52	1.52	1.52	Personal communication with Excellent Fixable Drapes	Per unit
Oxytocin*	1.25	1.25	1.25	1.25	18	Per patient. Cost includes oxytocin for initial infusion 10IU (0.42 USD) and maintenance infusion 20IU (0.84 USD).
Tranexamic acid (TXA) *	2.74	2.74	2.74	2.74	18	Per 1g/10mL ampoule
Administration of TXA	0.80	0.28	-	0.28	Personal communication with country TMGs	Per procedure. Cost includes 10 minutes of midwife time for slow bolus injection.
Intravenous (IV) fluids*	0.54	0.54	0.54	0.54	19	Per 500mL. Cost per mL is used across volumes.
IV fluid giving set and cannula*	0.38	0.38	0.38	0.38	26	Per unit
Ergometrine*	0.73	0.73	0.73	0.73	18	Per 200 mcg/ml injection in 1mL ampoule
Misoprostol*	1.25	1.25	1.25	1.25	18	Per 800mcg (4 x 200mcg tablets)
Hysterectomy	185.21	258.86	1339.49	138.91	24 4 25	Per procedure
Laparotomy	148.17	207.09	1071.59	111.13		Per procedure. Cost is 80% of postpartum hysterectomy cost
Non-pneumatic anti- shock garment (NASG)*	1.27	1.17	1.54	1.17	26	Per procedure, based on 72 uses o NASG.
Bimanual compression	2.40	0.85	6.35	0.86	²³ Personal communication with country TMGs	Per procedure, Assumption: 30 minutes of midwife time
Uterine balloon tamponade (UBT)*	1.19	0.93	6.90	0.93	26 27	Per procedure. For Kenya, Nigeria, and Tanzania the cost includes the components of UBT device (condom, catheter and syringe) an 5 minutes of midwife time. For South Africa the cost includes Ellav device.
Attending doctor for severe PPH	1.54	0.79	4.27	0.72	²³ Personal communication with country TMGs	Per case of severe PPH. Cost is 10 minutes of doctor time
Non-ICU hospitalisation	7.62	13.99	110.27	5.61	22	Per day in hospital. Cost estimates represent the hotel component of hospital costs, i.e., excluding the cost of drugs and diagnostic tests.
ICU admission	57.43	100.50	717.86	43.07	28	Per day in ICU
Transfer to higher level facility	19.35	34.25	54.74	14.51	24,25	Per event
Blood transfusion	95.64	40.08	288.55	71.73	4	Per procedure. Cost assumes 2 units of whole blood were require for blood transfusions.
Needles and syringe*	0.05	0.05	0.05	0.05	26	Per unit

Costing assumptions

Several simplifying assumptions were necessary to estimate unit costs in the analysis. These were based on expert clinical opinion from within the E-MOTIVE study team and findings from an observational study conducted alongside the trial. All assumptions were agreed prior to any analysis being undertaken.

- Staff time was only costed when additional labour was considered essential.
- For cases of *severe* PPH, it was assumed that a doctor would attend for 10 minutes. We considered the lowest appropriate grade doctor who could attend.
- To avoid zero costs, patients with a length of stay less than 24 hours were assigned the cost of a full day on the ward which can be considered as a proxy for the cost of delivery.
- Patients with an ICU length of stay less than 24 hours were assigned the cost of a full day in ICU.
- The duration of bimanual compression was assumed to be 30 minutes.
- Two units of whole blood were assumed to be required for those who needed blood transfusions.
- The cost of a cannula and an IV giving set were applied to half of the women who had IV PPH treatment, given observational findings showed that approximately 50% of patients had prior IV access.
- A one-off cost for syringes and needles for PPH treatment with oxytocin, TXA and ergometrine was applied.
- In the absence of robust costs for laparotomy across all countries, an assumed cost equivalent to 80% of a hysterectomy was applied.
- Uterine massage and examination of the genital tract were not assumed to bear an additional cost when
 delivered as part of the E-MOTIVE intervention. These aspects of the first-response treatment bundle were
 considered relevant to a reprioritisation of care and not additional care. It was expected to be delivered
 by the same attending midwife so extra resource would not be required.
- The costs of the uncalibrated drapes used by the usual-care group in the E-MOTIVE trial were not considered by this analysis as they were used for research purposes.

The importance of assumptions was explored using deterministic sensitivity analyses.

Table A2. Relative cost indices of participating countries based on WHO-CHOICE estimates							
To country:	From country:						
	Kenya	Nigeria	South Africa	Tanzania			
Kenya	1.00	0.57	0.08	1.34			
Nigeria	1.77	1.00	0.14	2.37			
South Africa	12.56	7.20	1.00	16.83			
Tanzania	0.75	0.42	0.06	1.00			

	E-MOTIVE	Usual care	
	(N = 48,678)	(N = 50,043)	
Uterine massage	5,762 (11.84)	4,085 (8.16)	
Oxytocin use	5,864 (12.05)	4,283 (8.56)	
Tranexamic acid use	5,796 (11.91)	1,965 (3.93)	
Intravenous fluids use	5,851 (12.02)	4,163 (8.32)	
Examination of the genital tract	5,476 (11.25)	3,581 (7.16)	
Ergometrine use	124 (0.25)	75 (0.15)	
Misoprostol use	2,587 (5.31)	2,705 (5.41)	
Laparotomy	1 (0.00)	3 (0.01)	
Hysterectomy	11 (0.02)	6 (0.01)	
Non-pneumatic anti-shock garment (NASG) use	89 (0.18)	38 (0.08)	
Bimanual compression	136 (0.28)	553 (1.11)	
Uterine balloon tamponade use	44 (0.09)	57 (0.11)	
Blood transfusion	1,063 (2.18)	1,286 (2.57)	
Transfer to higher level facility	82 (0.17)	17 (0.03)	
Intensive care unit (ICU) admissions	7 (0.01)	28 (0.06)	
Duration of hospitalisation (days)*	1.09 (1.78)	1.14 (2.06)	
Duration of ICU hospitalisation (days)*	2.00 (2.45)	1.57 (1.53)	

Values are number (percentage) or mean (SD)*

Baseline data before implementation of the intervention (107,733 patients in 78 clusters) for the E-MOTIVE and usual-care groups are as follows: *Uterine massage*: E-MOTIVE: 5,074 (10.00), usual care: 4,537 (7.96); *Oxytocin use*: E-MOTIVE: 5,740 (11.32), usual care: 4,063 (8.88); *Tranexamic acid use*: E-MOTIVE: 2,246 (4.43), usual care: 1,221 (2.14); *Intravenous fluid use*: E-MOTIVE: 5,289 (10.43), usual care: 4,458 (7.82); *Examination of the genital tract*: E-MOTIVE: 4,007 (7.90), usual care: 3,786 (6.64); *Ergometrine use*: E-MOTIVE: 131 (0.26), usual care: 162 (0.28); *Misoprostol use*: E-MOTIVE: 3,286 (6.48), usual care: 3,234 (5.67); *Laparotomy*: E-MOTIVE: 3 (0.01), usual care: 3 (0.01); *Hysterectomy*: E-MOTIVE: 7 (0.01), usual care: 8 (0.01); *NASG*: E-MOTIVE: 72 (0.14), usual care: 50 (0.09); *Bimanual compression*: E-MOTIVE: 303 (0.60), usual care: 438 (0.77); *Uterine balloon tamponade*: E-MOTIVE: 23 (0.05), usual care: 56 (0.11); *Blood transfusion*: E-MOTIVE: 1,474 (2.91), usual care: 1,652 (2.90); *Transfer to higher level facility*: E-MOTIVE: 74 (0.15), usual care: 23 (0.04); *ICU admissions*: E-MOTIVE: 13 (0.03), usual care: 39 (0.07); *Duration of hospitalisation (days)**: E-MOTIVE: 1.06 (2.31), usual care: 1.05 (1.79); *Duration of ICU hospitalisation (days)**: E-MOTIVE: 2.00 (1.96), usual care: 2.02 (3.09).

Table A4. Mean per-patient costs (2022 USD)						
	E-MOTIVE	Usual care	Adjusted	95% CIs**		
	(N= 48,678)	(N = 50,043)	Difference*			
Calibrated blood-collection	1.518	0.000	1.518	-		
drape	(0.000)	(0.000)				
Oxytocin	0.151	0.111	0.034	0.007 to 0.068		
	(0.408) 0.367	(0.357) 0.126				
Tranexamic acid use	(1.00)	(0.624)	0.252	0.199 to 0.305		
	0.216	0.162				
Intravenous fluids use	(0.582)	(0.512)	0.047	0.007 to 0.087 -0.019 to 0.026		
	0.066	0.068				
Misoprostol	(0.280)	(0.282)	0.004			
	0.002	0.001		0.000 to 0.003		
Ergometrine	(0.037)	(0.026)	0.002			
	0.006	0.005		0.000 to 0.002		
Needles and syringes	(0.016)	(0.014)	0.001			
	0.003	0.009		-0.019 to 0.005		
Laparotomy	(0.672)	(1.241)	-0.008			
	0.117	0.025		-0.030 to 0.228		
Hysterectomy	(10.875)	(2.333)	0.101			
Non-pneumatic anti shock	0.002	0.001	0.004	-0.001 to 0.003		
garment (NASG)	(0.051)	(0.035)	0.001			
Discound company of the	0.003	0.013	-0.004	-0.012 to 0.004		
Bimanual compression	(0.093)	(0.178)	-0.004			
Uterine balloon tamponade	0.002	0.001	0.000	-0.001 to 0.002		
(UBT)	(0.076)	(0.055)	0.000			
Blood transfusion	1.348	1.899	-0.088	-0.585 to 0.439		
Blood transfusion	(12.710)	(16.940)	-0.000			
Non-ICU hospitalisation	41.175	40.526	-1.718	-3.823 to 0.396		
Non-ico nospitalisation	(104.015)	(118.889)	-1.710			
ICU admission	0.037	0.439	0.194	-0.196 to 0.689		
	(3.996)	(31.238)	U.154	0.150 to 0.009		
Transfer to higher level	0.089	0.011	0.024	-0.001 to 0.047		
facility	(2.2017)	(0.707)	0.02-7	3.002 to 0.047		
Severe postpartum	0.034	0.0622	-0.027	-0.035 to -0.018		
haemorrhage (doctor time)	(0.334)	(0.3949)	0.02,	2.000 10 0.010		
Mean total cost (USD)	45.135	43.189	0.302	-2.312 to 2.783		
	(107.932)	(126.844)				

Values are mean (SD).

^{*}Adjusted for number of vaginal births per hospital, time period, country, the proportion of patients with a clinical primary-outcome event at each hospital and the quality of oxytocin at each hospital during the baseline phase and for clustering using random cluster and cluster-by-time effects.

^{**} Confidence intervals were constructed using non-parametric permutation tests, by finding the upper and lower boundaries of the intervention effect that would lead to a two-sided P value less than the 5% level (1000 replications).